Company intelligence / Profile preview

Liperate Therapeutics

Gwynedd Valley, Pennsylvania, United States

Ownership: Private
Development stage: Other

Overview

Liperate Therapeutics is a pre-clinical stage biotechnology company focused on developing novel small molecule therapies for inflammatory and fibrotic diseases. The company's lead program targets GPR84, a G protein-coupled receptor that plays a significant role in modulating immune cell activation and inflammatory responses. By inhibiting GPR84, Liperate aims to provide effective treatments for conditions such as ulcerative colitis and nonalcoholic steatohepatitis (NASH). The company is led by experienced industry veterans and is advancing its pipeline toward IND-enabling studies.

Therapeutic areas: GastroenterologyPulmonology
Modalities: Small molecule
Industry: Biotech

Drug pipeline

1 asset

ASITI-201

Unknown

Beyond the preview

Go deeper on Liperate Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Liperate Therapeutics.

Explore the full profile